Medical University of South Carolina

MEDICA
Pharmacy & Therapeutics Update: Drug Information for Health Care Professionals
6-1-2009

Pharmacy & Therapeutics Update: Drug Information for Health
Care Professionals, June 2009
Medical University of South Carolina
Heather Kokko
Medical University of South Carolina

Kelli Garrison
Medical University of South Carolina

Jason Cooper
Medical University of South Carolina

Chris Wisniewski
Medical University of South Carolina

See next page for additional authors

Follow this and additional works at: https://medica-musc.researchcommons.org/musc-ptupdate

Recommended Citation
Medical University of South Carolina; Kokko, Heather; Garrison, Kelli; Cooper, Jason; Wisniewski, Chris;
and Lewis, Ashley, "Pharmacy & Therapeutics Update: Drug Information for Health Care Professionals,
June 2009" (2009). Pharmacy & Therapeutics Update: Drug Information for Health Care Professionals. 34.
https://medica-musc.researchcommons.org/musc-ptupdate/34

This Newsletter is brought to you for free and open access by MEDICA. It has been accepted for inclusion in
Pharmacy & Therapeutics Update: Drug Information for Health Care Professionals by an authorized administrator
of MEDICA. For more information, please contact medica@musc.edu.

Authors
Medical University of South Carolina, Heather Kokko, Kelli Garrison, Jason Cooper, Chris Wisniewski, and
Ashley Lewis

This newsletter is available at MEDICA: https://medica-musc.researchcommons.org/musc-ptupdate/34

Pharmacy & Therapeutics
Pharmacy & Therapeutics Update

Update
Drug Information for
Health Care Professionals

Drug Information Center
Department of Pharmacy Services
RT Annex, Room 604
Phone: 792-3896
E-mail: druginfo@musc.edu
Visit us on the Web!
www.formularyproductions.com/musc

Editorial Staff
Heather Kokko, PharmD
Interim Director, Department of Pharmacy Services
Editor

Kelli Garrison, PharmD, BCPS
Manager, Medication Use Policy and Informatics
Editor

Jason Cooper, PharmD
Drug Information Specialist
Associate Editor and Newsletter Layout

Chris Wisniewski, PharmD, BCPS
Drug Information Specialist
Associate Editor

Ashley Lewis, PharmD
Resident, Drug Information Practice
Assistant Editor

In This Issue
▪ Transdermal Patches and
Magnetic Resonance Imaging
▪ Did You Know...
− ADR Reporting at MUSC
▪ Gluten Intolerance in
Celiac Disease
▪ Formulary Update: May 2009
▪ Formulary and Drug Information Resources Web Page

June 2009
Transdermal Patches and Magnetic Resonance Imaging
By: Daniel Miller, PharmD
PGY1 Pharmacy Resident
The Food and Drug Administration (FDA) recently issued a public
health advisory* stating that medication patches worn during MRI procedures may cause burns.1 Published reports have identified patients
who have suffered second degree burns while wearing either Habitrol®
(nicotine) or Deponit® (nitroglycerin) patches during an MRI procedure.1-5
Other transdermal drug
delivery systems identified as having potential to
cause the same reaction
are listed in Table 1.3,5
The concern traditionally
raised by MRI machines
and metal objects is the
potential for these objects
to be attracted by the
magnetic field and pulled
into the machine. 2
The problem observed
with transdermal patches
is somewhat different.

CASE REPORT: A 52-year-old male was scheduled
to undergo magnetic resonance imaging (MRI) of his
abdomen. Prior to beginning the procedure, the nurse
performed a routine screening, asking him whether he
was wearing jewelry, had any surgically implanted
devices or cardiac stents, or had been involved in any
sort of incident that may have introduced shrapnel
into his body. The patient answered “no” to all questions, and the procedure was started.
Approximately 5 minutes into the scan, the patient
began complaining of an intense burning in his arm.
Although he insisted he could continue the procedure,
the radiologist halted it immediately. Examination of
the right-upper arm revealed a nicotine patch, the skin
around which was red. The patch was removed and
the skin underneath was noted to be blistered. The
patient had suffered a second degree burn as a result
of wearing a nicotine patch during an MRI procedure.

Many medication patches contain a waterproof backing which contains
aluminum. Aluminum is nonferromagnetic, and therefore, not subject to
the forces induced by the magnetic field. It is, however, capable of concentrating electrical currents such as those created by the radiofrequency pulses emitted by the MRI machine. The electrical currents are
concentrated in the aluminum and the heat results from resistance to
electrical flow.
However, not all medication patches are capable of causing burns when
worn during an MRI procedure. For example, the contraceptive patch,
Ortho-Evra® has been shown to be MRI safe.5 It has been suggested
*FDA Public Health Advisory:
http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm111313.htm
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that the safety of a patch can be assessed by simply observing the patch for shininess and reflection of light,
the presence of which would indicate aluminum content.2,3
Table 1. Transdermal Delivery Systems That May
Cause Adverse Reactions During MRI Procedures
Brand Name

Generic Name

Androderm®

Testosterone
®

Catapress-TTS

Clonidine

Fentanyl

Fentanyl

®

Lidopel
Neupro

Lidocaine and epinephrine

®

Nicotrol HD

Rotigotine
®

Nicotine

Prostep®

Nicotine
®

Salonpas Powder Plus

Methyl salicylate/menthol

Synera®

Lidocaine and tetracaine

Transderm-scop

®

Scopolamine

However, this is not a reliable method as several
patches with clear backings contain metal ions that are
capable of conducting heat.4 To further complicate
matters, there are currently no requirements for
manufacturers to report MRI safety on their labeling.
It has been recommended that removal of any patch
prior to an MRI procedure occur if any doubt exists as
to the metal content of the patch.4,5
The FDA is currently in the process of reviewing all
transdermal products and ensuring that those containing metal have warnings in their labeling.4 The FDA
will also require a printed warning on the patch itself.
In the meantime, the risk of interruption of drug delivery should be evaluated and managed on an individual
patient basis.

Did You Know…
Adverse Drug Reactions (ADR) Reporting at MUSC
The Joint Commission requires hospitals to have an adverse drug reaction (ADR) surveillance program. MUSC collects
data regarding ADRs in order to improve overall patient safety. The information gathered is examined for specific
trends and potential problems with the administration of medications to our patients. The ultimate goal is to improve the
medication-use system.
An ADR is defined as being any unintended, undesired, unwarranted, or excessive reaction to a medication. At MUSC,
reactions are further classified as being either serious (ie, initial or prolonged hospitalization, life threatening, or death)
or preventable (ie, dose-related, previous allergy, failure to institute prophylactic therapy, or an extension of the pharmacological action of the medication). Those that are serious and preventable are further examined for ways to improve the
continuum of care. This information is collected monthly and reported to the Pharmacy and Therapeutics (P&T) Committee.
Common ADRs that are reported or occur in patients include reactions such as rashes from penicillin administration,
steroid-induced hyperglycemia, and allergic reactions (ie, hives, shortness of breath) from intravenous contrast media.
Examples of serious and preventable ADRs would be hypoglycemia from insulin administration, confusion/altered mental status associated with opioid use, and hypotension secondary to furosemide (Lasix®) administration. They would be
considered serious if the patient was admitted to the ER/hospital, which usually happens in these cases. These are also
considered to be preventable as they are often dose related (ie, too much given/prescribed).
Figures regarding the monthly ADRs that occur at MUSC are compiled primarily through eCodes (ie, chart reviews) and
Patient Safety Net (PSN) reporting. However, less than 10% of the total ADRs reported at MUSC are done so through
the PSN reporting system; therefore, it is important for all nurses, pharmacists, physicians, and other health care professionals that are caring for a patient that experienced an ADR to use PSN for accurate reporting.
The PSN icon can be found on any LYNX computer in the hospital. It takes approximately 5 to 10
minutes to complete the form online. Basic information such as the patient’s name, MRN, service,
location, and age are needed. Detailed information regarding the actual ADR can be entered in two
places; also, the dose and drug name are required, as well as the name and occupation of the reporter.
Again, the goal of the ADR program is not to punish one or a group of individuals for reporting an
ADR, but to improve the overall medication-use system.
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Gluten Intolerance in Celiac Disease
By: Chelsey Jensen, PharmD
PGY1 Pharmacy Practice Resident
Celiac Disease
Celiac disease, also known as celiac sprue, is a chronic immune
mediated disorder caused by a genetic intolerance to gluten.1-4,7,9,10
Once categorized as a pediatric
disorder characterized by diarrhea,
malabsorption and weight loss,
celiac disease is now commonly
recognized as a multi-system condition, which can be diagnosed at
any age.1,3 Celiac disease affects
over 3 million Americans, or
about 1 in 133 individuals.2-4,7
Among the population with a first
degree relative with celiac disease,
nearly 1 in 22 individuals are affected.2
Additionally, among
adults, 2 to 3 times as many
women have the disease than
men.1 On average, it takes about
9 years from the onset of symptoms for an individual to become
diagnosed with celiac disease.11
The Role of Gluten
The pathogenesis and clinical
manifestations of celiac disease
are precipitated by the ingestion of
gluten. Gluten is a protein derived
from wheat, barley, and rye and is
poorly digested in the upper gastrointestinal tract (GI) of humans.1,3 Gluten is the term that
describes the entire protein component of wheat; however, the
protein that is not tolerated by celiac patients is gliadin, a fraction
of gluten resistant to degradation
in the GI tract.1 Gliadin inappropriately triggers an immune response in individuals with celiac
disease, leading to a chronic inflammatory response and damage
to the proximal small intestinal

mucosa.1,3,4,5,7 Damage to the
villi in the small intestine can
impair digestion and absorption
of micro- and macronutrients
leading to a net secretion of water and solutes.5 Celiac disease
can present with intestinal or
malabsorption symptoms and/or
extraintestinal symptoms; however, individuals may also be
asymptomatic (Table 1).1,3,5,7
Extraintestinal symptoms are
often complications resulting
from persistent damage to the
small intestine including osteoporosis and iron deficiency anemia (Table 1).1,3,5,7,10 Additional
complications of celiac disease if
left untreated, include intestinal
adenocarcinoma, enteropathyassociated T-cell lymphoma, and
refractory celiac disease.1,3,4,8,10
Currently, the only accepted
treatment of celiac disease is nutritional therapy and life-long
elimination of gluten from the
diet.1,2,6 Gluten is found not only
in food but also in drugs and
cosmetics. The FDA requires
food labeling to mention gluten
contents; however, it does not
require the mention of gluten on
drug labels.9

Gluten in Foods
Gluten is commonly found in
wheat, barley, and rye products.
Table 2 provides examples of the
American Dietetic Association
recommendations for a gluten-free
diet.4,8 The complete celiac disease nutrition guide can be obtained from the American Dietetic
Association electronically at
www.eatright.org. Common gluten-free foods include tapioca,
corn, soy, rice, nuts, and legumes.
Processed foods such as french
fries, soup, candy (Table 2) and
other goods such as chapstick or
lipgloss may contain or become
contaminated with gluten during
the manufacturing process (Table
3), so it is important to check the
label or avoid these products.
Gluten in Drugs
The majority of gluten in pharmaceuticals derives from inactive
ingredients from whole grains,
grain flour, dusting powder, unspecified starch or pregelatinized
starch sources.9,10 Starches that are
derived from potato or corn
sources used for inactive ingredients should be acceptable to use,
unless contaminated with gluten.9
Table 4 provides electronic resources on celiac disease, including information about gluten content of pharmaceutical products.
When confirming gluten content
of pharmaceuticals, it is important
to periodically check with the
manufacturer because the source
of an inactive ingredient can be
changed without changing the
package label.9
References available upon request.
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Table 1: Potential clinical manifestations
in celiac disease3,6
Intestinal symptoms
Chronic diarrhea
Anorexia
Failure to thrive
Abdominal distension/bloating
Weight loss
Symptoms secondary to malabsorption
Iron deficiency anemia
Recurrent abortions
Short stature
Persistent abdominal pain
Osteopenia/osteoporosis

Table 3: Hidden Sources of Gluten7
Vitamins
Lipstick
Hydrolyzed
protein
Modified food
starch

Toothpaste
Communion
wafers
Imitation seafood
Playdough
Ice cream

Lipgloss
Dairy substitutes
Licorice
Seasonings

Chapstick
Dextrin
Lunch meat
Soy sauce

Table 4: Celiac Disease Resources10,11
Gluten free drugs
Celiac Disease Foundation
Celiac Sprue Association
The Celiac Disease and
Gluten-free Diet Support Center
Canadian Celiac Association
Gluten intolerance group of
North America

Extraintestinal symptoms
Dermatitis herpetiformis
Dental enamel hypoplasia
Persistent aphthous stomatitis
Ataxia
Hypertransaminasemia
Alopecia
Vasculitis

www.glutenfreedrugs.com
www.celiac.org
www.csaceliacs.org
www.celiac.com
www.celiac.ca
www.gluten.net

Table 2: American Dietetic Association Recommendations for Gluten-Free Diet4,8
Allowed Foods
Amaranth
Arrowroot
Buckwheat
Cassava
Corn
Flax
Indian rice grass

Job’s tears
Legumes
Millet
Nuts
Potatoes
Quinoa
Rice

Sago
Seeds
Soy
Sorghum
Tapioca
Wild rice
Yucca

Foods to Avoid
Wheat
▪ Einkorn, emmer, spelt, kamut
▪ Wheat starch, wheat bran, wheat germ, cracked wheat, hydrolyzed wheat protein

Barley
Rye
Triticale (a cross between wheat and rye)

Other Wheat Products
Bromated flour
Durum flour
Enriched flour
Farina

Graham flour
Phosphated flour
Plain flour

Self-rising flour
Semolina
White flour

Processed Foods that May Contain Wheat, Barley, or Rye*
Bouillon cubes
Brown rice syrup
Chips/potato chips
Candy
Cold cuts, hot dogs, salami,
Sausage

Communion wafer
French fries
Gravy
Imitation fish
Matzo
Rice mixes

Sauces
Seasoned tortilla chips
Self-basting turkey
Soups
Soy sauce
Vegetables in sauce

* Most of these foods can be found gluten-free. When in doubt, check with the food manufacturer.
** This is not a complete list, patients should be referred to a dietitian or physician specializing in celiac disease.
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FORMULARY UPDATE FOR MAY 2009
In May 2009, the Pharmacy and
Therapeutics Committee approved
the actions listed below. The formulary effective date was June
15, 2009.
CHANGES:
Enteral Nutrition Formulas:
Per the Nutrition Subcommittee,
the following changes were made
to the enteral nutrition formulary.
These changes were made to accommodate diabetic, renal, and
pediatric formulas.
ADDED: Novasource Renal®
DELETED: Nepro® with Carb
Steady
ADDED: Peptamen® 1.5
DELETED: Peptamen® AF
ADDED: Glucerna® 1.5
CHANGE IN RESTRICTION:
Internal Medicine physicians s
added to the list of services who
can prescribe methotrexate. This
was to accommodate patients admitted on oral methotrexate for
non-chemotherapy related diseases without having to obtain a
consult. See Chemotherapy Prescribing Privileges* for specifics
on what type of prescriber can
write orders for chemotherapeutic
agents

The updated formulary restriction for methotrexate is follows:
▪ Hematology/Oncology
▪ Dermatology
▪ Neurology
▪ Obstetrics/Gynecology
▪ Pulmonary and Critical Care
▪ Rheumatology
▪ Psychiatry [physicians double
board certified in Psychiatry/
Neurology or Psychiatry/
Internal Medicine]
▪ Internal Medicine
LINE EXTENSIONS:
▪ Nicotine (Nicorette®)
2-mg lozenge (mint);
2-mg gum (mint)
▪ Conivaptan (Vaprisol®)
20-mg/100 mL premix
infusion in dextrose 5%
▪ Iloprost (Ventavis®)
20-microgram/mL vial
DELETIONS:
▪ Conivaptan (Vaprisol®)
20-mg/4 mL vial
▪ Iloprost (Ventavis®)
10-microgram/mL vial
CHARTS, GUIDELINES,
AND ORDER FORMS:
The MUSC Albumin Use in
Adult Patients guidelines* were
updated to reflect new information and current practices. Also,

an automatic 24-hour stop order
was added to all standing albumin
orders. Physicians must now rewrite any albumin order after 24
hours.
The updated guidelines
were posted June 15th and can be
found under the “Medication Use
Policy” tab on Formulary and Drug
Information Resources web page.
The 24-hour stop order will go into
effect on July 1st.
The next meeting of the Pharmacy
and Therapeutics Committee will
be on June 30, 2009.
Drug Information Service
Monday - Friday
9:00 AM - 5:30 PM
792-3896

▪ Comprehensive information
concerning drug therapy

▪ Formulary management
▪ Patient-specific pharmacotherapy consultations

▪ Medication inservices
▪ Adverse drug reaction surveillance and management

▪ Medication use evaluations

*Formulary and Drug Information Resources Web Page*
http://www.formularyproductions.com/musc/
This web page contains access to medications and dosage forms available on the
formulary and all guidelines and dosing charts approved by the Pharmacy and
Therapeutics Committee. This link is located in the following places:
▪ MUSC Intranet: main page and Nursing Toolbox
▪ Clinicians Order Forms page

